Group interviewed | Study Arm 2 | Study Arm 3 | Total | ||
---|---|---|---|---|---|
Men | Women | Men | Women | ||
Refusers at screening phase | 2–4 | 2–4 | 2–4 | 2–4 | 8–16 |
Onchocerciasis negative and refuse ivermectin | 2–4 | 2–4 | 2–4 | 2–4 | 8–16 |
Refusers of doxycycline | 2–4 | 2–4 | 2–4 | 2–4 | 8–16 |
Acceptors of doxycycline | 6–12 | 6–12 | 6–12 | 6–12 | 24–48 |
Post-training interviews with CDDs | 2–4 | 2–4 | 2–4 | 2–4 | 8–16 |
Post-intervention interviews with CDDs | 2–4 | 2–4 | 2–4 | 2–4 | 8–16 |
Post-training interviews with chief of centre | 2–3 | 2–3 | 4–6 | ||
Post-intervention interviews with chief of centre | 2–3 | 2–3 | 4–6 | ||
Key Informant interviews with influential community members | 4–8 | 4–8 | 8–16 | ||
Ground larviciding implementers | na | 4–8 | 4–8 |